Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease-Reference-Cited by-同舟云学术

Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease

Published:2022-06-06 Issue:15 Volume:128 Page:2967-2977
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Desai Ami V.¹^ORCID,Applebaum Mark A.¹^ORCID,Karrison Theodore G.²,Oppong Akosua³,Yuan Cindy⁴,Berg Katherine R.⁵,MacQuarrie Kyle⁶^ORCID,Sokol Elizabeth⁶^ORCID,Hall Anurekha G.⁷,Pinto Navin⁷,Wolfe Ian⁸,Mody Rajen⁸,Shusterman Suzanne⁹,Smith Valeria¹⁰,Foster Jennifer H.¹⁰^ORCID,Nassin Michele¹,LaBelle James L.¹,Bagatell Rochelle⁵,Cohn Susan L.¹

Affiliation:

1. Department of Pediatrics University of Chicago Chicago Illinois

2. Department of Public Health Sciences University of Chicago Chicago Illinois

3. Pritzker School of Medicine University of Chicago Chicago Illinois

4. Department of Radiology University of Chicago Chicago Illinois

5. Children's Hospital of Philadelphia and the University of Pennsylvania Philadelphia Pennsylvania

6. Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University Chicago Illinois

7. Seattle Children's Hospital and University of Washington Seattle Washington

8. C. S. Mott Children's Hospital and University of Michigan Ann Arbor Michigan

9. Dana‐Farber/Boston Children's Cancer and Blood Disorders Center Harvard Medical School Boston Massachusetts

10. Texas Children's Hospital and Baylor College of Medicine Houston Texas

Funder